A phase I, randomized, double-blind, dose-ranging, crossover trial of HCV vaccine (TG4040) in patients with chronic hepatitis C to be conducted in two parts
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2008
At a glance
- Drugs TG 4040 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2008 Primary outcome identified as safety and virological response as reported by ClinicalTrials.gov.
- 14 Sep 2008 Planned end date added (1 Sep 2007) as reported by ClinicalTrials.gov.
- 18 May 2007 New trial record.